Journal Mobile Options
Table of Contents
Vol. 73, No. 3-4, 2007
Issue release date: April 2008
Oncology 2007;73:221–227

Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer

Boeck S. · Wilkowski R. · Bruns C.J. · Issels R.D. · Schulz C. · Moosmann N. · Laessig D. · Haas M. · Golf A. · Heinemann V.
Departments of aInternal Medicine III, and bSurgery, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, cPractice for Radiooncology and Radiotherapy, Klinik Bad Trissl, Oberaudorf, dGSF, National Research Center for Environment and Health, Neuherberg, and eDepartment of Medicine I, Buergerhospital, Klinikum Stuttgart, Stuttgart, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: To date, no standard regimen for salvage chemotherapy after gemcitabine (Gem) failure has been defined for patients with advanced pancreatic cancer (PC). Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in PC patients. Methods: Within a prospective single-center study, Cap was offered to patients who had already received at least 1 previous treatment regimen containing full-dose Gem (as a single agent, as part of a combination chemotherapy regimen or sequentially within a chemoradiotherapy protocol). Cap was administered orally at a dose of 1,250 mg/m2 twice daily for 14 days followed by 7 days of rest. Study endpoints were objective tumor response rate by imaging criteria (according to RECIST), carbohydrate antigen 19-9 (CA19-9) tumor marker response, time to progression, overall survival and toxicity. Results: A median of 3 treatment cycles (range 1–36) was given to 39 patients. After a median follow-up of 6.6 months, 27 patients were evaluable for response: no complete or partial responses were observed, but 15 patients (39%) had stable disease. A CA19-9 reduction of >20% after 2 cycles of Cap was documented in 6 patients (15%). Median time to progression was 2.3 months (range 0.5–45.1) and median overall survival (since start of Cap treatment) was 7.6 months (range 0.7–45.1). Predominant grade 2 and 3 toxicities (per patient analysis) were hand-foot syndrome 28% (13% grade 3); anemia 23%; leg edema 15%; diarrhea 13%; nausea/vomiting 10%, and leukocytopenia 10%. Conclusion: Single-agent Cap is a safe treatment option for Gem-pretreated patients with advanced PC. Further evaluation of Cap in controlled clinical trials of Gem-pretreated patients with advanced PC is recommended.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Ozols RF, Herbst RS, Colson YL, et al: Clinical cancer advances 2006: major research advanced in cancer treatment, prevention, and screening – a report from the American Society of Clinical Oncology. J Clin Oncol 2007;25:146–162.
  2. Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–2413.
  3. Heinemann V: Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 2002;29(suppl 20):9–16.
  4. Hochster HS, Haller DG, de Gramont A, et al: Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006;107:676–685.
  5. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960–1966.
  6. Cunningham D, Chau I, Stocken D, et al: Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer (abstract PS11). Eur J Cancer 2005;3(suppl):4.
  7. Oettle H, Pelzer U, Stieler J, et al: Oxaliplatin/folinic acid/5-fluorouracil (24 h) (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003) (abstract 4031). Proc Am Soc Clin Oncol 2005;23: 315s.

    External Resources

  8. Nakachi K, Furuse J, Ishii H, Suzuki E, Yoshino M: Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jap J Clin Oncol 2007;37:114–120.
  9. Oettle H, Arnold D, Esser M, Huhn D, Riess H: Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000;11:635–638.
  10. Milella M, Gelibter A, Di Cosimo S, et al: Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004;101:133–138.
  11. Cantore M, Rabbi C, Fiorentini G, et al: Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004;67:93–97.
  12. Tsavaris N, Kosmas C, Skopelitis H, et al: Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs 2005;23:369–375.
  13. Kulke MH, Blaszkowsky LS, Ryan DP, et al: Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007;25:4787–4792.
  14. Demols A, Peeters M, Polus M, et al: Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006;94:481–485.
  15. Reni M, Pasetto L, Aprile G, et al: Raltitrexed-eloxantin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 2006;94:785–791.
  16. Boeck S, Weigang-Köhler K, Fuchs M, et al: Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol 2007;18:745–751.
  17. Jacobs AD, Burris HA, Rivkin S, et al: A randomized phase III study of rubitecan (ORA) vs best choice (BC) in 409 patients with refractory pancreatic cancer. Report from a North-American multi-center study (abstract 4013). Proc Am Soc Clin Oncol 2004;22:316s.

    External Resources

  18. Cartwright TH, Cohn A, Varkey JA, et al: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2001;20:160–164.

    External Resources

  19. Scheithauer W, Schüll B, Ulrich-Pur H, et al: Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 2004;14:97–104.

    External Resources

  20. Stathopoulos GP, Syrigos K, Polyzos A, et al: Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol 2004;15:224–229.
  21. Herrmann R, Bodoky G, Ruhstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer. A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212–2217.
  22. Blom JW, Osanto S, Rosendaal FR: High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 220 patients. Eur J Cancer 2006;42:410–414.
  23. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Can Inst 2000;92:205–216.
  24. Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V: Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006;70:255–264.
  25. Tempero MA, Behrman S, Ben-Josef E, et al: Pancreatic adenocarcinoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2005;3:598–626 (for update, version V.I. 2008, see
  26. Xiong HQ, Wolff RA, Hess KR, et al: A phase II trial of oxaliplatin plus capecitabine (xelox) as second line therapy for patients with advanced pancreatic cancer (abstract 4119). Proc Am Soc Clin Oncol 2006;24:207s.

    External Resources

  27. Riess H, Pelzer U, Stieler J, et al: A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer – CONKO 003 (abstract 4517). Proc Am Soc Clin Oncol 2007;25:201s.
  28. Holen KD, Klimstra DS, Hummer A, et al: Clinical characteristics and outcome from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol 2002;20:4673–4678.
  29. Kitagami H, Kondo S, Hirano S, et al: Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from pancreatic cancer registry of Japan pancreas society. Pancreas 2007;35:42–46.
  30. Boeck S, Hinke A, Wilkowski R, Heinemann V: Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol 2007;13:224–227.
  31. Mancuso-Petricca A, Saletti P, Tronconi MC, et al: The efficacy of fluoropyrimidine-based second line chemotherapy in advanced and metastatic pancreatic cancer: results of an ongoing Italian/Swiss multicenter survey (abstract 1131P). Ann Oncol 2006;17(suppl 9):ix323.
  32. Fine RL, Fogelman DR, Schreibman SM, et al: The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 2008;61:167–175.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50